Daraxonrasib in Pancreatic Cancer: What GPs Should Know
The US FDA has approved daraxonrasib in pancreatic cancer. The drug, an oral RAS inhibitor, is indicated for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic therapy or are not candidates for multiagent systemic therapy. This is an important development in pancreatic cancer. Targeted treatments have previously been available mainly…